Mid- to Long-Term Clinical Outcomes of Patients Treated With the Everolimus-Eluting Bioresorbable Vascular Scaffold: The BVS Expand Registry

JACC: Cardiovascular Interventions

Volumn 9, Issue 16, 2016, Pages 1652-1663

  Felix, Cordula M ^a   Fam, Jiang Ming ^a   Diletti, Roberto ^a   Ishibashi, Yuki ^a   Karanasos, Antonios ^a   Everaert, Bert R C ^a   van Mieghem, Nicolas M D A ^a   Daemen, Joost ^a   de Jaegere, Peter P T ^a   Zijlstra, Felix ^a   Regar, Evelyn S ^a   Onuma, Yoshinobu ^a   van Geuns, Robert Jan M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Absorb bioresorbable vascular scaffold; BVS; coronary artery disease; follow up; mid to long term; percutaneous coronary intervention

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN; PRASUGREL; TICAGRELOR; BIOCOMPATIBLE COATED MATERIAL; CARDIOVASCULAR AGENT; EVEROLIMUS;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; BIORESORBABLE VASCULAR STENT; BLOOD VESSEL OCCLUSION; BRAIN HEMORRHAGE; CARDIAC IMAGING; CARDIOVASCULAR MORTALITY; CLINICAL EVALUATION; CLINICAL OUTCOME; CLINICAL PRACTICE; CONTROLLED STUDY; EVEROLIMUS ELUTING BIORESORBABLE VASCULAR SCAFFOLD; EVEROLIMUS ELUTING CORONARY STENT; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROSPECTIVE STUDY; SILENT MYOCARDIAL ISCHEMIA; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STABLE ANGINA PECTORIS; STENT THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; UNSTABLE ANGINA PECTORIS; VASCULAR ACCESS; ADVERSE EFFECTS; AGED; ANGINA, STABLE; ANGINA, UNSTABLE; BIODEGRADABLE IMPLANT; CORONARY DISEASE; CORONARY THROMBOSIS; DEVICES; DIAGNOSTIC IMAGING; KAPLAN MEIER METHOD; MORTALITY; NETHERLANDS; NON-ST ELEVATED MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PROSTHESIS DESIGN; RECURRENT DISEASE; REGISTER; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME;

ABSORBABLE IMPLANTS; AGED; ANGINA, STABLE; ANGINA, UNSTABLE; CARDIOVASCULAR AGENTS; COATED MATERIALS, BIOCOMPATIBLE; CORONARY DISEASE; CORONARY THROMBOSIS; EVEROLIMUS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NETHERLANDS; NON-ST ELEVATED MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; RECURRENCE; REGISTRIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84990879635     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2016.04.035     Document Type: Article

References (23)

1. 1 Joner, M., Finn, A.V., Farb, A., et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 48 (2006), 193–202.
2. 2 Raber, L., Magro, M., Stefanini, G.G., et al. Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study. Circulation 125 (2012), 1110–1121.
3. 3 Iqbal, J., Onuma, Y., Ormiston, J., Abizaid, A., Waksman, R., Serruys, P., Bioresorbable scaffolds: rationale, current status, challenges, and future. Eur Heart J 35 (2014), 765–776.
4. 4 Karanasos, A., Simsek, C., Gnanadesigan, M., et al. OCT Assessment of the long-term vascular healing response 5 years after everolimus-eluting bioresorbable vascular scaffold. J Am Coll Cardiol 64 (2014), 2343–2356.
5. 5 Simsek, C., Karanasos, A., Magro, M., et al. Long-term invasive follow-up of the everolimus-eluting bioresorbable vascular scaffold: five-year results of multiple invasive imaging modalities. EuroIntervention 11 (2016), 996–1003.
6. 6 Onuma, Y., Dudek, D., Thuesen, L., et al. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial. J Am Coll Cardiol Intv 6 (2013), 999–1009.
7. 7 Serruys, P.W., Chevalier, B., Dudek, D., et al. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet 385 (2015), 43–54.
8. 8 Kimura, T., Kozuma, K., Tanabe, K., et al. A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan. Eur Heart J 36 (2015), 3332–3342.
9. 9 Wohrle, J., Naber, C., Schmitz, T., et al. Beyond the early stages: insights from the ASSURE registry on bioresorbable vascular scaffolds. EuroIntervention 11 (2015), 149–156.
10. 10 Capodanno, D., Gori, T., Nef, H., et al. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention 10 (2015), 1144–1153.
11. 11 Cutlip, D.E., Windecker, S., Mehran, R., et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115 (2007), 2344–2351.
12. 12 Hermiller, J.B., Rutledge, D.R., Gruberg, L., et al. Sustained low clinical event rates in real-world patients receiving everolimus-eluting coronary stent system from a large, prospective, condition of approval study: 2-year clinical outcomes from the XIENCE V USA Study. J Interv Cardiol 25 (2012), 565–575.
13. 13 Abizaid, A., Ribamar Costa, J. Jr., Bartorelli, A.L., et al. The ABSORB EXTEND study: preliminary report of the twelve-month clinical outcomes in the first 512 patients enrolled. EuroIntervention 10 (2015), 1396–1401.
14. 14 Kraak, R.P., Hassell, M.E., Grundeken, M.J., et al. Initial experience and clinical evaluation of the Absorb bioresorbable vascular scaffold (BVS) in real-world practice: the AMC Single Centre Real World PCI Registry. EuroIntervention 10 (2015), 1160–1168.
15. 15 Ishibashi, Y., Nakatani, S., Onuma, Y., Definite and probable bioresorbable scaffold thrombosis in stable and ACS patients. EuroIntervention 11 (2015), e1–e2.
16. 16 Capodanno, D., Joner, M., Zimarino, M., What about the risk of thrombosis with bioresorbable scaffolds?. EuroIntervention 11 (2015), V181–V184.
17. 17 Everaert, B., Felix, C., Koolen, J., et al. Appropriate use of bioresorbable vascular scaffolds in percutaneous coronary interventions: a recommendation from experienced users : A position statement on the use of bioresorbable vascular scaffolds in the Netherlands. Neth Heart J 23 (2015), 161–165.
18. 18 Tamburino, C., Latib, A., van Geuns, R.J., et al. Contemporary practice and technical aspects in coronary intervention with bioresorbable scaffolds: a European perspective. EuroIntervention 11 (2015), 45–52.
19. 19 Karanasos, A., Van Mieghem, N., van Ditzhuijzen, N., et al. Angiographic and optical coherence tomography insights into bioresorbable scaffold thrombosis: single-center experience. Circ Cardiovasc Interv, 8, 2015 002369.
20. 20 Kolandaivelu, K., Swaminathan, R., Gibson, W.J., et al. Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation 123 (2011), 1400–1409.
21. 21 Okamura, T., Onuma, Y., Garcia-Garcia, H.M., et al. First-in-man evaluation of intravascular optical frequency domain imaging (OFDI) of Terumo: a comparison with intravascular ultrasound and quantitative coronary angiography. EuroIntervention 6 (2011), 1037–1045.
22. 22 Tu, S., Xu, L., Ligthart, J., et al. In vivo comparison of arterial lumen dimensions assessed by co-registered three-dimensional (3D) quantitative coronary angiography, intravascular ultrasound and optical coherence tomography. Int J Cardiovasc Imaging 28 (2012), 1315–1327.
23. 23 Robaei, D., Back, L.M., Ooi, S.Y., Pitney, M.R., Jepson, N., Everolimus-eluting bioresorbable vascular scaffold implantation in real world and complex coronary disease: procedural and 30-day outcomes at two Australian centres. Heart Lung Circ 24 (2015), 854–859.